Nitta Gelatin India Ltd
Incorporated in 1975, Nitta Gelatin India Ltd manufactures and sells ossein, gelatin, and collagen peptide[1]
- Market Cap ₹ 721 Cr.
- Current Price ₹ 794
- High / Low ₹ 988 / 640
- Stock P/E 9.62
- Book Value ₹ 465
- Dividend Yield 0.76 %
- ROCE 24.4 %
- ROE 19.6 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
- Company has delivered good profit growth of 46.1% CAGR over last 5 years
Cons
- The company has delivered a poor sales growth of 9.26% over past five years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
287 | 354 | 357 | 356 | 342 | 303 | 342 | 396 | 506 | 565 | 533 | 533 | |
271 | 330 | 321 | 320 | 313 | 273 | 306 | 351 | 442 | 452 | 409 | 429 | |
Operating Profit | 16 | 24 | 36 | 36 | 29 | 30 | 36 | 45 | 64 | 114 | 123 | 103 |
OPM % | 5% | 7% | 10% | 10% | 8% | 10% | 10% | 11% | 13% | 20% | 23% | 19% |
0 | 2 | 2 | 9 | 5 | 1 | 2 | 1 | 5 | 4 | 11 | 24 | |
Interest | 8 | 10 | 8 | 7 | 7 | 9 | 8 | 6 | 5 | 4 | 3 | 1 |
Depreciation | 17 | 14 | 13 | 14 | 15 | 15 | 16 | 16 | 14 | 14 | 15 | 14 |
Profit before tax | -9 | 1 | 18 | 24 | 12 | 7 | 13 | 25 | 49 | 99 | 116 | 112 |
Tax % | -23% | 358% | 53% | 49% | 61% | 33% | 8% | 29% | 29% | 25% | 28% | 25% |
-7 | -4 | 9 | 12 | 5 | 5 | 12 | 18 | 35 | 74 | 84 | 84 | |
EPS in Rs | -6.71 | -1.56 | 11.82 | 15.61 | 4.90 | 3.82 | 12.38 | 19.15 | 36.26 | 77.44 | 91.02 | 92.45 |
Dividend Payout % | 0% | -64% | 21% | 16% | 51% | 39% | 20% | 16% | 11% | 10% | 7% | 11% |
Compounded Sales Growth | |
---|---|
10 Years: | 4% |
5 Years: | 9% |
3 Years: | 2% |
TTM: | 0% |
Compounded Profit Growth | |
---|---|
10 Years: | 48% |
5 Years: | 46% |
3 Years: | 32% |
TTM: | -9% |
Stock Price CAGR | |
---|---|
10 Years: | 18% |
5 Years: | 51% |
3 Years: | 39% |
1 Year: | -18% |
Return on Equity | |
---|---|
10 Years: | 16% |
5 Years: | 22% |
3 Years: | 24% |
Last Year: | 20% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 |
Reserves | 100 | 99 | 105 | 124 | 139 | 141 | 144 | 164 | 192 | 259 | 334 | 413 |
68 | 66 | 92 | 109 | 104 | 108 | 84 | 80 | 86 | 39 | 14 | 31 | |
49 | 49 | 50 | 59 | 54 | 55 | 57 | 53 | 58 | 60 | 65 | 62 | |
Total Liabilities | 226 | 223 | 256 | 301 | 306 | 313 | 294 | 306 | 345 | 367 | 423 | 515 |
125 | 118 | 120 | 110 | 113 | 130 | 121 | 113 | 107 | 114 | 114 | 117 | |
CWIP | 9 | 9 | 9 | 13 | 10 | 4 | 4 | 2 | 7 | 7 | 8 | 19 |
Investments | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 7 |
92 | 96 | 127 | 177 | 182 | 179 | 169 | 191 | 230 | 246 | 300 | 372 | |
Total Assets | 226 | 223 | 256 | 301 | 306 | 313 | 294 | 306 | 345 | 367 | 423 | 515 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
24 | 20 | 20 | 11 | 27 | 22 | 40 | 19 | 17 | 101 | 94 | 75 | |
-24 | -8 | -14 | -3 | -7 | -14 | -10 | -7 | -14 | -18 | -54 | -9 | |
0 | -12 | 18 | -5 | -20 | -7 | -33 | -12 | -2 | -55 | -36 | 11 | |
Net Cash Flow | -1 | 0 | 25 | 3 | -0 | 1 | -3 | -0 | 1 | 28 | 4 | 77 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 28 | 23 | 21 | 54 | 66 | 76 | 37 | 58 | 64 | 57 | 58 | 65 |
Inventory Days | 131 | 100 | 114 | 144 | 153 | 191 | 205 | 161 | 136 | 126 | 156 | 136 |
Days Payable | 72 | 51 | 42 | 48 | 53 | 59 | 49 | 43 | 28 | 39 | 44 | 39 |
Cash Conversion Cycle | 87 | 72 | 93 | 150 | 165 | 209 | 193 | 176 | 172 | 144 | 170 | 162 |
Working Capital Days | 62 | 54 | 58 | 97 | 94 | 108 | 78 | 107 | 113 | 90 | 97 | 106 |
ROCE % | -0% | 6% | 13% | 14% | 7% | 6% | 9% | 12% | 20% | 33% | 35% | 24% |
Documents
Announcements
-
Announcement Under Regulation 30 Of SEBI (LODR) Regulations, 2015- Amendment To PIT Policies
8h - Nitta Gelatin amends insider trading code per SEBI regulations, enhancing fair disclosure and trading conduct policies.
-
Announcement Under Regulation 30 Of SEBI (LODR) Regulations- (Appointment Of Secretarial Auditor)
9h - Appointment of SEP & Associates as Secretarial Auditor for five years from FY 2025-26.
-
Announcement under Regulation 30 (LODR)-Change in Directorate
9h - Re-appointment of Independent Director Dr. M. Jaichandren for 4 years from 04.08.2025.
-
Results- Financial Results (31.03.2025)
9h - Audited FY25 results approved; Rs.8/share dividend recommended including Rs.2 special dividend.
-
Board Meeting Intimation for Approving The Audited Financial Results (Standalone And Consolidated) For The Quarter And Financial Year Ended 31St March, 2025 And For Recommending Dividend If Any.
21 Apr - Board meeting on May 2, 2025, to approve FY25 results and consider dividend.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Business Overview:[1]
NGIL, a joint venture between the Kerala State Industrial Development Corporation (32% shareholding) and Osaka-based NGI (43% stake), manufactures gelatin, ossein, limed ossein, and DCP from processed animal bones. It also produces collagen peptide-based consumer products for the pharmaceutical and healthcare industries.